【科技自立·产业自强】美康生物：VAP检测技术填补国内技术空白 正式进入临床应用阶段

Core Viewpoint - Meikang Bio has developed the VAP (Vertical Auto Profile) technology for precise lipid testing, addressing the high incidence and mortality rates of atherosclerosis in China, thus filling a technological gap in the domestic market [1] Group 1: Technology Development - The VAP technology can directly measure 15 subcomponents of lipoprotein cholesterol and particle concentration levels, providing precise diagnostic indicators for the etiology of atherosclerosis [1] - The technology has officially entered the standardized clinical application phase, promoting the development of clinical lipid management towards precision [1]